Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Non-Current Assets (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Non-Current Assets data on record, last reported at $474.3 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 18.09% year-over-year to $474.3 million; the TTM value through Dec 2025 reached $2.1 billion, down 21.93%, while the annual FY2025 figure was $474.3 million, 18.09% down from the prior year.
  • Non-Current Assets reached $474.3 million in Q4 2025 per MRVI's latest filing, down from $523.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.6 billion in Q3 2023 and bottomed at $474.3 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $1.0 billion, with a median of $926.2 million recorded in 2021.
  • Peak YoY movement for Non-Current Assets: surged 53.75% in 2022, then tumbled 61.76% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $1.2 billion in 2021, then grew by 21.74% to $1.4 billion in 2022, then crashed by 45.1% to $787.5 million in 2023, then dropped by 26.47% to $579.1 million in 2024, then decreased by 18.09% to $474.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $474.3 million in Q4 2025, $523.3 million in Q3 2025, and $537.2 million in Q2 2025.